Vitamin D3
Dietary Supplementdaily dosage of 50 µg Vitamin D3 for 8 weeks
Other names: cholecalciferol
NCT Number: NCT01501916
The aim of this study is to investigate whether a supplementation of Vitamin D3 can be used to reduce atherosclerotic risk factors.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
It is the objective of this study to investigate whether a supplementation with Vitamin D3 can be used to reduce atherosclerotic risk factors such as hypertension, inflammation and hyperlipidemia. The research question is whether Vitamin D3 can lower blood pressure in mildly hypertensive subjects who are naive to antihypertensive medication, whether Vitamin D reduces the level of systemic inflammation and whether Vitamin D3 has an effect on blood lipids.
major outcomes:
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
daily dosage of 50 µg Vitamin D3 for 8 weeks
Other names: cholecalciferol
daily intake of placebo
Time frame: after 8 weeks of supplementation
major outcome variable is the decrease oy systolic blood pressure in the treatment group in comparison with the placebo group.
Martin-Luther-Universität Halle-Wittenberg
Other
Effect of Vitamin D3 on Cardiovascular Risk Factors: a Randomized Trial in Human
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03074851
Cardiovascular Diseases, Hypertension
Changzhi, Shanxi, China
View Trial DetailsNCT02299388
Cardiovascular Diseases, Diabetes Mellitus
New Orleans, Louisiana, United States
View Trial DetailsNCT02655029
Adherence to Medication Regime, Behavior
Athens, Greece
View Trial DetailsNCT01897155
Agnosia, Cardiovascular Diseases
Santiago, Santiago Metropolitan, Chile
View Trial Details